Use of nanodispersions in pharmaceutical end formulations

Details Use of nanodispersions in pharmaceutical end formulations Use of nanodispersions in pharmaceutical end formulations

2011-01-18

2011-01-18

Kishore, Gollamudi S (Department: 1612)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C424S401000, C264S004100, C264S004300, C264S004600, C514S937000, C514S938000

Reexamination Certificate

active

07871642

ABSTRACT:
A nanodispersion comprises(a) a membrane-forming molecule,(b) a coemulsifier and(c) a lipophilic component,in pharmaceutical end formulations, the nanodispersion being obtainable by(α) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and(β) adding the liquid obtained in step (α) to the water phase of the pharmaceutical end formulations, where steps (α) and (β) may be carried out without high energy mixing or homogenization.The nanodispersions prepared according to this invention are suitable as transport vehicles for pharmaceutical active agents.

REFERENCES:
patent: 4816247 (1989-03-01), Desai et al.
patent: 4874850 (1989-10-01), Paradies
patent: 5162377 (1992-11-01), Kakoki et al.
patent: 5190936 (1993-03-01), Laugier et al.
patent: 5338761 (1994-08-01), Nakajima et al.
patent: 5444041 (1995-08-01), Owen et al.
patent: 5472706 (1995-12-01), Friedman et al.
patent: 5633226 (1997-05-01), Owen et al.
patent: 5646109 (1997-07-01), Owen et al.
patent: 5658898 (1997-08-01), Weder et al.
patent: 5688761 (1997-11-01), Owen et al.
patent: 5997888 (1999-12-01), Weder et al.
patent: 6028067 (2000-02-01), Hong et al.
patent: 6245349 (2001-06-01), Yiv et al.
patent: 19522693 (1997-01-01), None
patent: 0082437 (1983-06-01), None
patent: 0280394 (1988-08-01), None
patent: 0 349 150 (1989-06-01), None
patent: 0349150 (1990-03-01), None
patent: 0429248 (1991-05-01), None
patent: 92/18147 (1992-10-01), None
patent: 93/02664 (1993-02-01), None
patent: 93/05767 (1993-04-01), None
patent: 93/18752 (1993-09-01), None
patent: 94/26252 (1994-11-01), None
patent: 95/16441 (1995-06-01), None
patent: 96/13273 (1996-05-01), None
patent: 96/37192 (1996-11-01), None
patent: 97/21428 (1997-06-01), None
Abstract for EP 0082437, Publication date Jun. 29, 1983.
Abstract for DE 19522693, Publication date Jan. 2, 1997.
CTFA On-Line, Sorbitan Derivative (Jul. 1, 2005).
Wade, Jr., L.G., Organic Chemistry, 2ndedition, p. 1059, (1991).
POE Sorbitan Oleate EO 20, www.chemicalland21.com/arokorhi/specialychem/perchem/polyoxyethylene%20SOR, 3/3, last visited May 10, 2005.
Van Nostrand's Scientific Encyclopedia, Sixth Edition, vol. 1, p. 514, (1982).
Glossary of Chemical Terms, Hampel and Hawley, p. 48, (1976).

Affiliated with

Also associated with

Rating

Use of nanodispersions in pharmaceutical end formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of nanodispersions in pharmaceutical end formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of nanodispersions in pharmaceutical end formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2706427